Desk edition Search
Amino Wire

Wire

Peptide regulation, testing & market news

27 stories · 21 explainers · 15 status logs · 33 tracked events

MarketSYDNEY · OCT 19 2026

NSW: 1,180 peptide-linked ER visits, most name retatrutide

Monthly visits went from five to more than 217 in 15 months. Retatrutide, a drug not approved anywhere, came up in 833 of them.

  • NSW Health surveillance data: 1,180 emergency department presentations associated with peptide use between July 1, 2025 and September 30, 2026.
  • Monthly presentations rose from five in July 2025 to more than 217 in September 2026, according to the Minister for Health's release.
  • Retatrutide was mentioned in 833 presentations, the Newcastle Herald reported from the same data. About 18 percent ended in a hospital admission.
  • NSW Health says none of the peptides it named (BPC-157, GHK-Cu, TB-500, retatrutide, CJC-1295) is approved in Australia for any purpose.

Read the story

The wire

All news

Explainers: start here

Regulation desk

Vendor status board

Full log
Vendor status, alphabetical. Facts only, no rankings.
Seller (A–Z)Record
Biotech PeptidesObserved
Core PeptidesObserved
Gram PeptidesFDA letter
NuScience PeptidesFDA letter
Paradigm PeptidesCourt case
Peak Performance PeptidesFDA letter
Peptide PartnersFDA letter
Peptide SciencesClosed

Showing 8 of 15 · alphabetical · see all

Edition built October 19, 2026. Every story links to its primary records. Editorial standards · Corrections